Abstract: Studies toward the synthesis of three biologically active [5, 6] -benzannulated spiroketal natural products are described. The first total synthesis of paecilospirone is reported, employing a late-stage, pH-neutral spiroketalization. A formal synthesis of γ-rubromycin is described, where the spiroketal moiety is formed by delicate manipulation of the electronic properties of the spirocyclization precursor. Finally, model work toward the total synthesis of berkelic acid is summarized, introducing a novel Horner-Wadsworth-Emmons/oxa-Michael (HWE/oxa-M) cascade to access the spiroketal precursor.
INTRODUCTION
There is a continual need to develop new drug candidates, not only to find potential treatments for diseases that currently have no cure, but also to combat increasingly common drug-resistant diseases. Nature has traditionally been the most important source of lead compounds for the development of new therapeutic agents owing to the vast biochemical diversity that has resulted from evolutionary selection pressures. The importance of natural products in the development of new drugs is highlighted by the recently published statistic that 53 % of new chemical entities approved for use in the clinic are compounds derived from knowledge gained from natural products [1] . Therefore, the total synthesis of natural products remains an essential branch of organic chemistry.
The spiroketal moiety is a common architectural feature found in many biologically active natural products [2] . However, benzannulated spiroketals isolated from natural products are considerably less prevalent [3] . Herein we provide an overview of our recent work in the area of [5, 6] -benzannulated spiroketal natural product synthesis. We summarize our recently completed total syntheses of γ-rubromycin [4] and paecilospirone [5] and our model studies toward berkelic acid [6] .
BERKELIC ACID
In the search for new sources of novel, biologically active natural products, chemists are increasingly turning to organisms that live in extreme environments [7] . A number of novel compounds have been isolated from these sources, which often display interesting biological activity and structural motifs. These so-called extremophiles have been found in habitats of high and low temperature, high pressure, high salt, and high and low pH. Berkelic acid belongs to the latter category, having been isolated as a secondary metabolite from a Penicillium species collected from Berkeley Pit Lake, a flooded former copper mine in Montana, USA, whose waters have a pH of ~2.5 and contain a number of heavy metals in high concentrations [8] . Berkelic acid was found to inhibit caspase-1 (GI 50 98 μM) and matrix metallo protease-3 (GI 50 1.87 μM) as well as exhibiting selective activity against the ovarian cancer cell line OVCAR-3 (GI 50 91 nM). Berkelic acid was originally assigned by Stierle and co-workers as having the relative stereochemistry 1, with the configuration of the C-22 quaternary center unknown (Fig. 1) . The potent biological activity of the molecule coupled with its remarkable structural architecture and ambiguity of the chemical structure has led to a number of efforts toward its total synthesis. The group of Fürstner determined the chirality at C-22 to be (S) and reassigned the stereochemistry of the C-18 and C-19 center by total synthesis of the methyl ester of berkelic acid [9] . The absolute stereochemistry was subsequently determined by total synthesis of the free acid by Snider et al., confirming the structure of berkelic acid as 2 [10] . Further total and formal syntheses have since been reported by the groups of De Brabander [11] and Pettus [12] .
We wished to develop a synthesis of berkelic acid using a flexible and convergent approach that would allow future manipulation of its biological activity through analogue synthesis. Our retrosynthetic analysis of the tetracyclic core of berkelic acid 3 is outlined in Scheme 1. We envisaged that isochroman 4 would spontaneously undergo spiroketalization upon global debenzylation under acidic conditions. In turn, isochroman 4 could be accessed from phosphonate 6 and lactol 7 by a Horner-Wadsworth-Emmons/oxa-Michael (HWE/oxa-M) cascade via enone 5. This approach provides increased flexibility compared to previous routes, with the stereochemistry installed at a late stage and the HWE/oxa-M cascade allowing access to a range of berkelic acid analogues by reacting any 2-benzyl oxy benzannulated lactol with a library of β-keto phosphonates in two simple operations. The synthesis of phosphonate 6 was accomplished by ring-opening of γ-butyrolactone (8) with potassium hydroxide and in situ trapping of the resulting hydroxy acid with benzyl bromide under Dean-Stark conditions (Scheme 2). Addition of lithium dimethyl methylphosphonate to the resulting benzyl ester afforded coupling partner 6.
Our initial strategy to lactone 14 required the toluate anion addition of benzyl-protected methyl orsellinate 11 [13] to the Weinreb amide of hexanoic acid to afford ketone 16 (Scheme 3). However, after extensive screening of reagents and conditions we were unable to effect this transformation. Instead, methyl ester 11 was converted to its corresponding diethyl amide 12 with trimethylaluminumdiethylamine complex. Pleasingly, amide 12 proved more amenable to the toluate anion addition chemistry, providing access to ketone 13 in good yield. Lactone 14 could now be accessed via a chiral reduction-cyclization strategy. We found that the highest level of enantiocontrol in the reduction step was provided by (S)-methyl-CBS to afford the corresponding hydroxy amide in 51 % ee. Cyclization to the lactone required harsh conditions, resulting in partial deprotection of the ortho benzyl ether. Subsequent reprotection with benzyl bromide and silver(I) oxide provided lactone 14 in moderate yield. In order to increase the level of enantiocontrol in the chiral reduction step, amide 13 was transformed to methyl ester 16 via isocoumarin 15. Methyl ester 16 rapidly reconverted to isocoumarin 15 upon exposure to acid or base, but with careful handling could be subjected to further manipulation. Reduction with (L)-TarB-NO 2 followed by cyclization of the resulting hydroxyl ester provided lactone 14 with an improved 73 % ee. Lactone 14 could be obtained in >99 % ee by a facile preparatory-scale high-performance liquid chromatography (HPLC) separation. Lactone 14 was reduced with diisobutylaluminum (DIBAL) to the corresponding lactol, which was added directly to deprotonated phosphonate 6, triggering the desired HWE/oxa-M cascade to afford isochroman 4 as a 1:1 mixture of diastereoisomers (Scheme 4). This mixture could be equilibrated with HCl in tetrahydrofuran (THF) to provide predominantly the undesired trans-isomer. However, when the 1:1 mixture of cis-and trans-isomers were subjected to the deprotection/cyclization conditions, we were delighted to find that the desired cis-configured tetracyclic core 3 was obtained exclusively, as evidenced by a strong nOe interaction between H-3'a and H-5'. The tetracyclic core 3 was obtained as a 14:1 mixture of diastereoisomers around the spiroketal center, with the major isomer being tentatively assigned as the anomerically stabilized compound, owing to the lack of an nOe correlation between H3'a and H-3. The observed equilibration is in agreement with a study of a similar tetracyclic model of berkelic acid, in which a mixture of four possible spiroketals underwent equilibration to a single isomer upon treatment with acid [14] .
RUBROMYCIN
The rubromycins are a family of structurally related natural products that contain a highly oxygenated naphthoquinone moiety and an isocoumarin unit. With the exception of α-rubromycin (21), these two fragments are connected through an optically active [5, 6] -spiroketal ring system. β-Rubromycin and γ-rubromycin have attracted interest as lead compounds for the development of anticancer drugs owing to their potent activity against human telomerase (IC 50 = 3 μM) [15] . It seems likely that the spiroketal moiety is an essential pharmacophore for the inhibition of telomerase as α-rubromycin (21) displays substantially decreased potency (IC 50 > 200 μM) [14e]. A number of related natural products also contain the aromatic spiroketal motif, such as purpuromycin (18) [16], a potential topical agent for vaginal infections and heliquinomycin (19) [17], a selective inhibitor of DNA helicase.
The unprecedented structural architecture and varied biological activity of this family of natural products have attracted considerable attention from the synthetic community [18] . However, despite these substantial efforts, only two successful total syntheses of the rubromycin family had been achieved when we started our investigations in this area. Danishefsky and co-workers completed their synthesis of heliquinomycin (19) in 2001 [19] , which was followed six years later by the total synthesis of γ-rubromycin (17) by Kita et al. [20] .
The low success rate for the total synthesis of the rubromycin family can be mainly attributed to difficulties assembling the spiroketal core under acidic conditions. Despite this seemingly straightforward approach, difficulties in spiroketalization have been reported by the groups of Danishefsky [19] , Kozlowski [21] , and Reissig [18, 22] in their work toward purpuromycin (18) and heliquinomycin (19) . Through the attempted spiroketalization of a number of model compounds, Kozlowski [21] and Reissig [18, 22] proposed that the presence of electron-withdrawing groups on the isocoumarin moiety decreases the nucleophilicity of the phenolic OH group owing to inductive and mesomeric effects (see inset, Fig. 2 ), reducing the efficiency of the critical spiroketalization step.
Previous work within our group has led to a mild and efficient spiroketalization protocol for the synthesis of a number of bisbenzannulated spiroketal compounds [23] . We proposed that this methodology could be extended to the synthesis of γ-rubromycin by the spiroketalization of an appropriate isocoumarin ring precursor that possesses the correct electronics to allow the formation of the spiroketal. This led us to disconnect the molecule to ketone 23 (Scheme 5), whereby the mesomeric effect of the isocoumarin is eliminated (see inset, Fig. 2 ). We hoped that subjecting 23 to acid conditions would pro- Our synthesis of the acetylene fragment commenced from known bromoquinone 27 (Scheme 6) [24] . Interestingly, allyloxylation of 27 resulted in a mixture of regioisomers, where substitution had occurred at both C-2 and C-3. We found that by changing the leaving group, the regiochemistry of the reaction could be controlled to favor either isomer. Allyloxylation of the corresponding iodide resulted in the exclusive formation of the C-3 substituted allyl ether, whereas azidoquinone 28 provided the desired C-2 substituted product 29 with excellent stereocontrol. A microwave-assisted Claisen rearrangement of 29 afforded the corresponding naphthol product in good yield, which was smoothly protected as its ethoxymethyl (EOM) ether 30. Reductive dimethylation of 30 required the careful use of a reductive environment (hydrogen atmosphere and sodium dithionite) with cesium carbonate as a base to obtain good conversion to naphthalene 31. Oxidative cleavage of the terminal olefin followed by addition of ethynyl magnesium bromide to the resulting aldehyde provided acetylene 25.
The synthesis of iodide fragment 26 commenced by para-selective bromination of commercially available guaiacol (32) with N-bromosuccinimide (NBS), followed by protection of the phenol as its EOM ether 33 (Scheme 7). Addition of deprotonated dimethyl malonate to bromophenol 33 and subsequent deprotection of the EOM ether afforded diester 34. Iodination was performed by treatment of 34 with tetramethylammonium dichloroiodate. Reprotection of the free phenol with EOMCl provided key coupling partner 26.
afforded 22, completing a formal synthesis of γ-rubromycin. Following the publication of this work, the Pettus group have since described a total synthesis of γ-rubromycin utilizing a late-stage [3 + 2] cycloaddition between a naphthoquinone and an exocyclic enol ether [25] .
PAECILOSPIRONE
Isolated in 2000 from the marine fungus Paecilomyces Sp. by Namikoshi and co-workers, paecilospirone (36) contains a novel spiro[chroman-2,1'(3'H)-isobenzofuran] core (Fig. 3) [26] . It was identified as a potential antimitotic agent (20 % inhibition at 50 μM) using an assay screening for microtubule assembly inhibitors. Despite the isolation of paecilospirone more than a decade ago, no total synthesis of this natural product has yet been reported [27] .
Our retrosynthetic strategy to paecilospirone (36) was based on a late-stage formation of the spiroketal moiety by deprotection of an appropriate precursor such as 37 (Scheme 9). However, initial studies showed that the hydroxyl group β to the spiroketal center underwent facile elimination under acidic conditions. This observation can be explained by the antiperiplanar relationship between the hydroxyl group and the H-9 proton. Based on these observations, judicious choice of protecting group was required so that the key deprotection/spiroketalization could be carried out under neutral conditions. We proposed that bis-allyl ether 37 would undergo Pd 0 -catalyzed deprotection and in situ spiroketalization. In turn, 37 could be accessed from an aryllithium addition of bromide 38 to aldehyde 39. Disconnection of 39 through an anti-selective aldol addition leads to aldehyde 40 and an appropriate chiral auxiliary 41. Our approach to aldehyde 39 commenced with the allyl protection of known phenol 42 [28] , followed by reduction of the aldehyde with sodium borohydride (Scheme 10). The resulting alcohol 43 was protected as its tert-butyldimethylsilyl (TBS) ether, which was subjected to a lithium-halogen exchange/formylation procedure to afford aldol precursor 40. The anti-aldol reaction was found to proceed in the highest yields by the use of the lactate-derived CH(OBz)Me auxiliary. Accordingly, the addition of aldehyde 40 to the boron enolate of ketone 44 provided aldol product 45 in good yield, as an inseparable 3:1 mixture of diastereoisomers. Protection of the secondary alcohol with triethylsilyl trifluoromethanesulfonate (TESOTf) allowed separation of the diastereoisomers by chromatography. The absolute stereochemistry of 45 was unambiguously determined by X-ray crystallography of a derivative [29] . Reduction of the benzoate ester with LiBH 4 followed by oxidative cleavage of the resulting glycol provided aldehyde 39 as the single (4R,5S) isomer.
Known benzaldehyde 46 [30] , readily synthesized from salicylaldehyde, was converted into bromide 38 in three steps (Scheme 11). Benzyl protection of the phenol, followed by reduction of the aldehyde and allylation of the resulting alcohol provided 38 in good yield. Lithium-halogen exchange of bromide 38 by treatment with nBuLi and subsequent addition to aldehyde 39 afforded the corresponding alcohol in moderate yield. Attempts to improve the yield of the coupling by the use of tBuLi were unsuccessful, resulting in the partial cleavage of the phenolic allyl ether. Oxidation of the resulting alcohol with DMP provided ketone 37. The stage was then set for the key pH-neutral spiroketalization step. Pleasingly, treatment of 37 with Pd 0 and PMHS-ZnCl 2 resulted in smooth deallylation/spiroketalization to afford 47 in good yield as an inseparable 3.5:1 mixture of diastereoisomers, with no dehydration products observed. The major diastereoisomer was determined to be the anomerically stabilized isomer by analysis of nOe interactions. The required C 8 alkyl chain was introduced by selective deprotection of the primary TBS ether, followed by oxidation of the resulting alcohol with tetrapropylammonium perruthenate (TPAP) and Grignard addition of octyl magnesium bromide to afford alcohol 48. At this point, the two anomeric diastereoisomers were readily separable by chromatography. The major isomer was then converted to paecilospirone (36) by oxidation of the benzylic alcohol and stepwise deprotection of the benzyl and triethylsilyl (TES) ethers. This route represents the first reported total synthesis of paecilospirone (36), and one that is scalable and highly amenable to the production of analogues for future biological investigations.
CONCLUSIONS
The strategies employed toward the synthesis of three spiroketal natural products, γ-rubromycin, paecilo spirone, and berkelic acid, have been described. The spiroketal moiety was introduced at a late stage in the synthesis of all three compounds, by deprotection of a ketone containing two appropriately protected OH groups. Three varied strategies were employed for the preparation of each of the three spiroketal precursors, namely, use of a Sonogashira coupling, aryllithium addition, and an HWE/oxa-M cascade for the syntheses of γ-rubromycin, paecilospirone, and berkelic acid, respectively.
